118 related articles for article (PubMed ID: 14676441)
21. Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma.
Shibuya M; Kondo F; Sano K; Takada T; Asano T
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):537-43. PubMed ID: 21234612
[TBL] [Abstract][Full Text] [Related]
22. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract.
Maitra A; Murakata LA; Albores-Saavedra J
Am J Clin Pathol; 2001 May; 115(5):689-94. PubMed ID: 11345832
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
24. p62 Expression in primary carcinomas of the digestive system.
Qian HL; Peng XX; Chen SH; Ye HM; Qiu JH
World J Gastroenterol; 2005 Mar; 11(12):1788-92. PubMed ID: 15793865
[TBL] [Abstract][Full Text] [Related]
25. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular carcinomas show abnormal expression of fibronectin protein.
Torbenson M; Wang J; Choti M; Ashfaq R; Maitra A; Wilentz RE; Boitnott J
Mod Pathol; 2002 Aug; 15(8):826-30. PubMed ID: 12181267
[TBL] [Abstract][Full Text] [Related]
27. X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues.
Sakemi R; Yano H; Ogasawara S; Akiba J; Nakashima O; Fukahori S; Sata M; Kojiro M
Oncol Rep; 2007 Jul; 18(1):65-70. PubMed ID: 17549347
[TBL] [Abstract][Full Text] [Related]
28. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.
Fan Z; van de Rijn M; Montgomery K; Rouse RV
Mod Pathol; 2003 Feb; 16(2):137-44. PubMed ID: 12591966
[TBL] [Abstract][Full Text] [Related]
29. Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas.
Zhao CL; Hui Y; Wang LJ; Yang D; Yakirevich E; Mangray S; Huang CK; Lu S
Hum Pathol; 2018 Oct; 80():76-81. PubMed ID: 29883780
[TBL] [Abstract][Full Text] [Related]
30. Aberrant expression of a fetal glycoprotein 68 in hepatocellular carcinoma: a comparative study on the expression of alpha-fetoprotein and carcinoembryonic antigen.
Kato M; Shinozawa T; Kato S; Terada T
Histol Histopathol; 2004 Jul; 19(3):701-6. PubMed ID: 15168330
[TBL] [Abstract][Full Text] [Related]
31. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma.
Wieczorek TJ; Pinkus JL; Glickman JN; Pinkus GS
Am J Clin Pathol; 2002 Dec; 118(6):911-21. PubMed ID: 12472285
[TBL] [Abstract][Full Text] [Related]
32. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Leong AS; Sormunen RT; Tsui WM; Liew CT
Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma.
Ishizawa T; Masuda K; Urano Y; Kawaguchi Y; Satou S; Kaneko J; Hasegawa K; Shibahara J; Fukayama M; Tsuji S; Midorikawa Y; Aburatani H; Kokudo N
Ann Surg Oncol; 2014 Feb; 21(2):440-8. PubMed ID: 24254203
[TBL] [Abstract][Full Text] [Related]
34. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
35. CEACAM5 has different expression patterns in gastric non-neoplastic and neoplastic lesions and cytoplasmic staining is a marker for evaluation of tumor progression in gastric adenocarcinoma.
Liu JN; Wang HB; Zhou CC; Hu SY
Pathol Res Pract; 2014 Oct; 210(10):686-93. PubMed ID: 25042385
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
37. Immunoreactivity of hepatocyte paraffin 1 monoclonal antibody in cutaneous metastatic tumors.
Kanitakis J; Chouvet B; Claudy A; Scoazec JY
Am J Clin Pathol; 2004 Jul; 122(1):85-9. PubMed ID: 15272534
[TBL] [Abstract][Full Text] [Related]
38. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.
Ramos-Vara JA; Miller MA; Johnson GC
Vet Pathol; 2001 Nov; 38(6):636-43. PubMed ID: 11732796
[TBL] [Abstract][Full Text] [Related]
40. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
